Meeting
2019 ASCO Annual Meeting
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
Authors
Elizabeth Jimenez Aguilar
Dana-Farber Cancer Institute, Boston, MA
Elizabeth Jimenez Aguilar , Biagio Ricciuti , Justin F. Gainor , Mizuki Nishino , Anika E. Adeni , Safiya Subegdjo , Sara Khosrowjerdi , Rachel Peterson , Subba Digumarthy , Corinne Liu , Jennifer L. Sauter , Hira Rizvi , Kathryn Cecilia Arbour , Brett W. Carter , John Heymach , Mehmet Altan , Matthew David Hellmann , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9111)
DOI
10.1200/JCO.2019.37.15_suppl.9111
Abstract #
9111
Poster Bd #
434
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2021 ASCO Annual Meeting
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.
First Author: Hiroshi Takumida
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2019 ASCO Annual Meeting
Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
First Author: Michael Leapman